This site is intended for healthcare professionals

Arvinas Inc., and Pfizer Inc., announce a global collaboration to develop and commercialize PROTAC Protein degrader ARV 471.

Read time: 1 mins
Last updated:1st Aug 2021
Published:1st Aug 2021
Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV 471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers.
Condition: Breast Cancer ER+ HER2 -
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest